课题基金 / 基金详情

Design and Testing of a Parechovirus Vaccine Vector

Design and Testing of a Parechovirus Vaccine Vector
副肠孤病毒疫苗载体的设计和测试
批准号:
6799387
负责人:
PAUL A KROGSTAD
金额:
$19.15万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-03-01 至 2006-02-28

项目摘要

项目成果

PAUL A KROGSTAD的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Induction of a mucosal immune response will be an essential attribute of a successful vaccine to block transmission of HIV infection. Studies in the SIV animal model system have demonstrated that immune responses following mucosal exposure to viral vectors and peptides can blunt the replication and pathogenesis of SIV after infection. Viral vectors based on two members of the poliovirus and coxsackievirus have been employed in some of these studies. The use of these and similar enteroviruses is attractive, as they replicate in lower gastrointestinal tract, and are likely to produce immune responses in both the gastrointestinal and genital tracts. However, safety concerns and plans to completely curtail the circulation of poliovirus are likely to dampen enthusiasm for using these specific viruses as vaccine vectors. The parechoviruses are closely related, but biologically distinct picornaviruses that appear naturally attenuated relative to coxsackie and polioviruses strains employed to date. Of particular importance, serious complications of parechovirus have been only rarely reported, even after infection of infants. We propose to construct and complete the initial in vitro testing of a parechovirus based vaccine vector, based on strategies already employed in the successful construction of enteroviral vectors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of a Novel Inhibitor of Enterovirus Replication
HIV REPLICATION AND THYMOPOIESIS IN ADOLESCENTS
DEVELOPMENTAL EXPRESSION OF COXSACKIE ADENOVIRUS RECEPTOR
  • 批准号:
    7958619
  • 项目类别:
  • 资助金额:
    $3.48万
  • 财政年份:
    2009
  • 负责人:
    PAUL A KROGSTAD
  • 依托单位:
HIV REPLICATION AND THYMOPOIESIS IN ADOLESCENTS
海外基金